{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:44:48Z","timestamp":1789469088345,"version":"build-2803163510"},"reference-count":243,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Following the first approval for prostate cancer (PCa) treatment of competitive antagonists of the androgen receptor (AR) function that bind to the androgen-binding pocket, much progress has been achieved regarding compound efficacy and specificity. Second-generation compounds and androgen synthesis blockers are now standard-of-care AR pathway inhibitors given to PCa patients. More recently, approaches targeting AR regions other than the ligand-binding domain (LBD), stimulating proteasome-mediated AR degradation, or bringing together the AR with an effector protein (EP) in prostate tumor cells, have been explored and, in several cases, clinically tested. Compounds blocking AR mRNA splicing or directly addressing AR splice variants, especially the constitutively active AR-V7 form, are also being evaluated. In addition, there are ongoing efforts aiming at impairing the function of essential AR cofactors, mainly those involved in downstream gene transcription and chromatin modulation. Alternative techniques to impair AR activity, such as nanoparticle formulations and targeting biomolecular condensates are furthermore being explored. Here we present the most recent developments in these different strategies to target the AR, directly or indirectly, for a more potent and long-lasting blockade. This will hopefully soon lead to treatments that improve progression-free and overall survival in PCa patients, while maintaining a good safety profile.<\/jats:p>","DOI":"10.3390\/ijms27188200","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:31:57Z","timestamp":1789464717000},"page":"8200","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives"],"prefix":"10.3390","volume":"27","author":[{"given":"Paulina J.","family":"Dziuba\u0144ska-Kusibab","sequence":"first","affiliation":[{"name":"Research and Early Development Oncology, Pharmaceuticals, Bayer AG, M\u00fcllerstr. 178, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Jourdan","sequence":"additional","affiliation":[{"name":"Research and Early Development Oncology, Pharmaceuticals, Bayer AG, M\u00fcllerstr. 178, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-0663","authenticated-orcid":false,"given":"Bernard","family":"Haendler","sequence":"additional","affiliation":[{"name":"Research and Early Development Oncology, Pharmaceuticals, Bayer AG, M\u00fcllerstr. 178, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0140-6736(25)02221-4","article-title":"Prostate cancer","volume":"407","author":"Fonteyne","year":"2026","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Nevedomskaya, E., Baumgart, S.J., and Haendler, B. (2018). Recent advances in prostate cancer treatment and drug discovery. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051359"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1530\/EO-22-0065","article-title":"Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer","volume":"2","author":"Leach","year":"2022","journal-title":"Endocr. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"116338","DOI":"10.1016\/j.biopha.2024.116338","article-title":"Androgen receptor cofactors: A potential role in understanding prostate cancer","volume":"173","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1758835920978134","DOI":"10.1177\/1758835920978134","article-title":"Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer","volume":"12","author":"Lavaud","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","article-title":"A new old target: Androgen receptor signaling and advanced prostate cancer","volume":"62","author":"Westaby","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/oncolo\/oyae019","article-title":"Extended safety and tolerability of darolutamide for nonmetastatic castration-resistant prostate cancer and adverse event time course in ARAMIS","volume":"29","author":"Shore","year":"2024","journal-title":"Oncologist"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Shore, N.D., George, D.J., Khan, N., Constantinovici, N., Chen, G., Ghadessi, M., Hlebec, V., and Morgans, A.K. (2026). Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study. Prostate Cancer Prostatic Dis., 1\u20138.","DOI":"10.1038\/s41391-026-01099-3"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MOU.0000000000000984","article-title":"Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management","volume":"32","author":"Jazayeri","year":"2022","journal-title":"Curr. Opin. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrurol.2014.243","article-title":"Emerging mechanisms of enzalutamide resistance in prostate cancer","volume":"11","author":"Claessens","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Feng, Q., and He, B. (2019). Androgen receptor signaling in the development of castration-resistant prostate cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00858"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.annonc.2025.10.1236","article-title":"Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer","volume":"37","author":"Virtanen","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s12276-025-01624-9","article-title":"Regulation of androgen receptor expression by enhancer elements in prostate cancer","volume":"58","author":"Khadka","year":"2026","journal-title":"Exp. Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17588359251379416","DOI":"10.1177\/17588359251379416","article-title":"The future of androgen receptor targeting in prostate cancer: Third-generation inhibitors and beyond","volume":"17","author":"Naoun","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_17","first-page":"42","article-title":"Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer","volume":"6","author":"Huang","year":"2026","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Dahiya, U.R., and Heemers, H.V. (2022). Analyzing the androgen receptor interactome in prostate cancer: Implications for therapeutic intervention. Cells, 11.","DOI":"10.3390\/cells11060936"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Cicchetti, R., Basconi, M., Litterio, G., Orsini, A., Mascitti, M., Digiacomo, A., Salzano, G., Tataru, O.S., Ferro, M., and Giulioni, C. (2025). Therapeutic advances in metastatic prostate cancer: A journey from standard of care to new emerging treatment. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311665"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/14656566.2026.2652456","article-title":"Evaluation of novel treatments for metastatic castration-resistant prostate cancer","volume":"27","author":"Guner","year":"2026","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.euf.2025.10.011","article-title":"Real-world treatment patterns and survival in metastatic castration-resistant prostate cancer: A systematic review of observational studies","volume":"12","author":"Raval","year":"2026","journal-title":"Eur. Urol. Focus"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2548975","DOI":"10.1080\/07853890.2025.2548975","article-title":"Mechanisms of neuroendocrine differentiation in castration-resistant prostate cancer and advances in the treatment of neuroendocrine prostate cancer","volume":"57","author":"Shao","year":"2025","journal-title":"Ann. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12672-026-04482-7","article-title":"Neuroendocrine prostate cancer (NEPC) in focus: State of the art and future prospectives","volume":"17","author":"Giunta","year":"2026","journal-title":"Discov. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-23-0593","article-title":"The genomic and epigenomic landscape of double-negative metastatic prostate cancer","volume":"83","author":"Lundberg","year":"2023","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41467-021-27322-4","article-title":"Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states","volume":"13","author":"Song","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e186599","DOI":"10.1172\/JCI186599","article-title":"Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer","volume":"135","author":"Roudier","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12943-026-02617-6","article-title":"Integrated single-cell and spatial transcriptomic profiling decodes lineage plasticity and immune microenvironment remodeling in prostate cancer progression","volume":"25","author":"Yu","year":"2026","journal-title":"Mol. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Liu, W., Kong, W., Jiang, S., Wei, Y., Yu, Z., Cao, X., Yang, J., Wei, X., Shen, L., and Qin, C. (2026). Integrative transcriptomic profiling reveals subtype-specific therapeutic vulnerabilities and resistance mechanisms in prostate cancer. BMC Cancer, 26.","DOI":"10.1186\/s12885-025-15357-5"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s41588-025-02139-9","article-title":"Spatially resolved transcriptomic analysis of the adult human prostate","volume":"57","author":"Hu","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41585-021-00561-2","article-title":"Prostate luminal progenitor cells: From mouse to human, from health to disease","volume":"19","author":"Baures","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9949","DOI":"10.1038\/s41467-024-54364-1","article-title":"Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer","volume":"15","author":"Kiviaho","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2415308122","DOI":"10.1073\/pnas.2415308122","article-title":"Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer","volume":"122","author":"Pitzen","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/s44321-026-00375-y","article-title":"Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy","volume":"18","author":"Baures","year":"2026","journal-title":"EMBO Mol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Nevedomskaya, E., and Haendler, B. (2022). From omics to multi-omics approaches for in-depth analysis of the molecular mechanisms of prostate cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116281"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1038\/s41467-025-60654-z","article-title":"Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer","volume":"16","author":"Mizuno","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","article-title":"An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer","volume":"23","author":"Davies","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"bqac153","DOI":"10.1210\/endocr\/bqac153","article-title":"Homing in on a moving target: Androgen receptor cistromic plasticity in prostate cancer","volume":"163","author":"Eickhoff","year":"2022","journal-title":"Endocrinology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/nar\/gkac1158","article-title":"Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression","volume":"51","author":"Zhang","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Yavuz, S., Abraham, T.E., Houtsmuller, A.B., and van Royen, M.E. (2024). Phase separation mediated sub-nuclear compartmentalization of androgen receptors. Cells, 13.","DOI":"10.3390\/cells13201693"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/13543784.2025.2573647","article-title":"Androgen receptor pathway signaling inhibitors in development for prostate cancer therapy","volume":"34","author":"Bleve","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.bmcl.2013.02.056","article-title":"Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer","volume":"23","author":"Bradbury","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1158\/1535-7163.MCT-12-1174","article-title":"AZD3514: A small molecule that modulates androgen receptor signaling and function in vitro and in vivo","volume":"12","author":"Loddick","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10637-015-0235-5","article-title":"AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer\u2014Results of two parallel first-in-human phase I studies","volume":"33","author":"Omlin","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/1878-0261.13641","article-title":"TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer","volume":"18","author":"Yoshida","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1200\/JCO.2021.39.15_suppl.5031","article-title":"First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant activity, in patients with metastatic castration-resistant prostate cancer refractory to abiraterone and\/or enzalutamide and chemotherapy","volume":"39","author":"Cook","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11045","DOI":"10.1021\/acs.jmedchem.1c00439","article-title":"Exploration and biological evaluation of basic heteromonocyclic propanamide derivatives as SARDs for the treatment of enzalutamide-resistant prostate cancer","volume":"64","author":"He","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-19-1458","article-title":"Orally bioavailable androgen receptor degrader, potential next-generation therapeutic for enzalutamide-resistant prostate cancer","volume":"25","author":"Ponnusamy","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10637-026-01600-8","article-title":"Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534","volume":"44","author":"Chrostek","year":"2026","journal-title":"Investig. New Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"118259","DOI":"10.1016\/j.ejmech.2025.118259","article-title":"Development of dual AR\/ARV7 degraders with 3,5-dimethylisoxazole to overcome antiandrogen resistance in castration-resistant prostate cancer","volume":"301","author":"Zhang","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e70700","DOI":"10.7554\/eLife.70700","article-title":"Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer","volume":"12","author":"Wu","year":"2023","journal-title":"eLife"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic\u2014A new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Su, G., Wang, Y., and Yao, L. (2026). Research trends and emerging frontiers in proteolysis targeting chimeras (PROTACs): A bibliometric analysis of 2630 publications (2001\u20132025). Pharmaceuticals, 19.","DOI":"10.3390\/ph19070988"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1021\/jacs.2c00874","article-title":"Hijacking methyl reader proteins for nuclear-specific protein degradation","volume":"144","author":"Nalawansha","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e70192","DOI":"10.1002\/ddr.70192","article-title":"Next-generation proteolysis-targeting chimeras in precision oncology: Multifunctional designs, emerging modalities, and translational prospects in targeted protein degradation","volume":"86","author":"Nafie","year":"2025","journal-title":"Drug Dev. Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Faryal, B., Ul Abideen, Z., Irfan, M., Ahmed, H., Jalilov, F., Abduraximova, L., and Ashraf, G.A. (2026). Targeted protein degradation in cancer: PROTACs, new targets, and clinical mechanisms. Biomolecules, 16.","DOI":"10.3390\/biom16020325"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e202100270","DOI":"10.1002\/cbic.202100270","article-title":"Recent developments in PROTAC-mediated protein degradation: From bench to clinic","volume":"23","author":"Hu","year":"2022","journal-title":"Chembiochem"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Chen, Q.H., Munoz, E., and Ashong, D. (2024). Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer. Cancers, 16.","DOI":"10.3390\/cancers16030663"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"107234","DOI":"10.1016\/j.phrs.2024.107234","article-title":"PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer","volume":"205","author":"Zhang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting Chimera androgen receptor degrader","volume":"24","author":"Snyder","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1158\/1078-0432.CCR-26-0253","article-title":"Phase 1b trial of bavdegalutamide (ARV-110) in combination with abiraterone for metastatic prostate cancer","volume":"32","author":"Smoragiewicz","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1200\/JCO.2024.42.16_suppl.5011","article-title":"ARV-766, a proteolysis targeting chimera androgen receptor degrader, in metastatic castration-resistant prostate cancer: Initial results of a phase 1\/2 study","volume":"42","author":"Petrylak","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/1078-0432.CCR-25-0471","article-title":"Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader and antagonist, for the treatment of advanced prostate cancer","volume":"32","author":"Nayak","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"16346","DOI":"10.1021\/acs.jmedchem.6c01590","article-title":"Discovery of potential first-in-class dual ligand-directed degrader and antagonist of the androgen receptor: BMS-986365","volume":"69","author":"Mortensen","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10637-025-01533-8","article-title":"Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: Results on safety, pharmacokinetics, and anti-tumor activity","volume":"43","author":"Azad","year":"2025","journal-title":"Investig. New Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1021\/acs.jmedchem.5c03138","article-title":"Discovery of AZD9750, an orally bioavailable androgen receptor degrader for the treatment of prostate cancer","volume":"69","author":"Scott","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"TPS5146","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS5146","article-title":"Phase I\/II study to evaluate AZD9750, a novel androgen receptor proteolysis-targeting chimera, alone and in combination with other agents in patients with metastatic prostate cancer (ANDROMEDA)","volume":"44","author":"Agarwal","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8586","DOI":"10.1021\/acs.orglett.5c02505","article-title":"Stereoselective synthesis of trans-3-amino-2,2,4,4-tetramethylcyclobutanol","volume":"27","author":"Zell","year":"2025","journal-title":"Org. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"ND02","DOI":"10.1158\/1538-7445.AM2025-ND02","article-title":"GDC-2992: A heterobifunctional androgen receptor (AR) antagonist and degrader for the treatment of AR wild-type and mutant prostate cancer","volume":"85","author":"Metcalfe","year":"2025","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"118580","DOI":"10.1016\/j.ejmech.2026.118580","article-title":"Small-molecule modulators of the androgen receptor N-terminal domain: Advances in medicinal chemistry for prostate cancer","volume":"305","author":"Sekhon","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1021\/acs.jmedchem.3c00585","article-title":"Discovery of BWA-522, a first-in-class and orally bioavailable PROTAC degrader of the androgen receptor targeting N-terminal domain for the treatment of prostate cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"117079","DOI":"10.1016\/j.ejmech.2024.117079","article-title":"Discovery of a highly potent, N-terminal domain-targeting degrader of AR-FL\/AR-V7 for the treatment of prostate cancer","volume":"282","author":"Ha","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101253","DOI":"10.1016\/j.neo.2025.101253","article-title":"Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer","volume":"71","author":"Hung","year":"2026","journal-title":"Neoplasia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"104500","DOI":"10.1016\/j.ebiom.2023.104500","article-title":"Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer","volume":"90","author":"Hung","year":"2023","journal-title":"eBioMedicine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1535-7163.MCT-20-0417","article-title":"Effects of MTX-23, a novel PROTAC of androgen receptor splice variant-7 and androgen receptor, on CRPC resistant to second-line antiandrogen therapy","volume":"20","author":"Lee","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"16593","DOI":"10.1021\/acs.jmedchem.5c01463","article-title":"Discovery of LYA914, an orally bioavailable PROTAC degrader targeting the DNA binding domain of the androgen receptor for the treatment of CRPC","volume":"68","author":"Lv","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8688","DOI":"10.1021\/acs.jmedchem.5c03330","article-title":"New PROTAC designs for targeted protein degradation in 2021\u20132025: Novel E3 ligases and pre-PROTACs","volume":"69","author":"Peng","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) caused by genomic alterations in core components of E3 ligase complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"eabn2707","DOI":"10.1126\/scisignal.abn2707","article-title":"The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells","volume":"15","author":"Kurimchak","year":"2022","journal-title":"Sci. Signal."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2024.07.005","article-title":"Regulated induced proximity targeting chimeras-RIPTACs\u2014A heterobifunctional small molecule strategy for cancer selective therapies","volume":"31","author":"Raina","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"103774","DOI":"10.1016\/j.drudis.2023.103774","article-title":"RIPTACs: A groundbreaking approach to drug discovery","volume":"28","author":"Ma","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1538-7445.AM2023-1629","article-title":"Prostate cancer RIPTAC therapeutics demonstrate activity in preclinical models of enzalutamide-resistant prostate cancer","volume":"83","author":"Yu","year":"2023","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"10503","DOI":"10.1021\/acs.jmedchem.5c01250","article-title":"RIPTACs for precision cancer therapy: A novel modality with the inspiration of HLD-0915 as the first candidate in clinical trials","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_86","first-page":"TPS5115","article-title":"An oral prostate cancer RIPTAC therapeutic in phase 1 for metastatic castrate resistant prostate cancer","volume":"43","author":"Armstrong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-018-0085-0","article-title":"Alternative splicing in prostate cancer","volume":"15","author":"Paschalis","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41388-024-03036-x","article-title":"Alternative splicing in prostate cancer progression and therapeutic resistance","volume":"43","author":"Rawat","year":"2024","journal-title":"Oncogene"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Henry, I., Foreman, R., Balachandran, L., Mortimer, E., and Asim, M. (2025). Emerging therapeutic approaches to engage the androgen receptor for the treatment of castration-resistant prostate cancer. Cancers, 17.","DOI":"10.3390\/cancers17233755"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e168649","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"115089","DOI":"10.1016\/j.celrep.2024.115089","article-title":"Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer","volume":"44","author":"Poluben","year":"2025","journal-title":"Cell Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","article-title":"ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer","volume":"35","author":"Cato","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1002\/1878-0261.13164","article-title":"Androgen receptor-mediated transcriptional repression targets cell plasticity in prostate cancer","volume":"16","author":"Erdmann","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_95","first-page":"343","article-title":"Androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer: Molecular mechanisms and therapeutic strategies","volume":"44","author":"Li","year":"2026","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.prnil.2025.12.002","article-title":"AR-V7 expression in primary non-metastatic prostate cancer and its role in disease progression following initial therapy: A systematic review and meta-analysis","volume":"14","author":"Quintanilha","year":"2026","journal-title":"Prostate Int."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10637-021-01202-6","article-title":"A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer","volume":"40","author":"Vaishampayan","year":"2022","journal-title":"Investig. New Drugs"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"oyaf434","DOI":"10.1093\/oncolo\/oyaf434","article-title":"EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naive metastatic hormone-sensitive prostate cancer","volume":"31","author":"Jang","year":"2026","journal-title":"Oncologist"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/onc.2013.284","article-title":"Mechanisms of the androgen receptor splicing in prostate cancer cells","volume":"33","author":"Liu","year":"2014","journal-title":"Oncogene"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"13426","DOI":"10.1038\/srep13426","article-title":"The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7","volume":"5","author":"Stockley","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"10461","DOI":"10.1073\/pnas.1706076114","article-title":"Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF","volume":"114","author":"Takayama","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e169200","DOI":"10.1172\/JCI169200","article-title":"The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer","volume":"133","author":"Adamson","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e198264","DOI":"10.1172\/JCI198264","article-title":"Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells","volume":"136","author":"Brittain","year":"2026","journal-title":"J. Clin. Investig."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e47678","DOI":"10.7554\/eLife.47678","article-title":"Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer","volume":"8","author":"Munkley","year":"2019","journal-title":"eLife"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1038\/s41388-020-01429-2","article-title":"Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing","volume":"39","author":"Shah","year":"2020","journal-title":"Oncogene"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/1878-0261.13728","article-title":"Targeting the CLK2\/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression","volume":"19","author":"Perina","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1007\/s11010-025-05302-2","article-title":"YTHDC1 orchestrates oncogenic splicing via the CLK1-SRSF1 splicing machinery to regulate castration-resistant prostate cancer progression","volume":"480","author":"Gupta","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/1541-7786.MCR-23-0958","article-title":"Defining splicing factor requirements for androgen receptor variant synthesis in advanced prostate cancer","volume":"22","author":"Walker","year":"2024","journal-title":"Mol. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Takayama, K.I. (2019). Splicing factors have an essential role in prostate cancer progression and androgen receptor signaling. Biomolecules, 9.","DOI":"10.3390\/biom9040131"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1038\/s41388-019-0696-7","article-title":"Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis","volume":"38","author":"Verhaegh","year":"2019","journal-title":"Oncogene"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"115712","DOI":"10.1016\/j.bmc.2020.115712","article-title":"The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells","volume":"28","author":"Melnyk","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13046-024-02986-0","article-title":"Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer","volume":"43","author":"Naro","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/ijc.30893","article-title":"Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer","volume":"141","author":"Wang","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1158\/1535-7163.MCT-11-0329","article-title":"Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer","volume":"10","author":"Zhang","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/bjc.2013.619","article-title":"First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer","volume":"109","author":"Bianchini","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.molcel.2023.05.017","article-title":"Minor intron splicing is critical for survival of lethal prostate cancer","volume":"83","author":"Augspach","year":"2023","journal-title":"Mol. Cell"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12672-015-0239-9","article-title":"Moving beyond the androgen receptor (AR): Targeting AR-interacting proteins to treat prostate cancer","volume":"7","author":"Foley","year":"2016","journal-title":"Horm. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ajpath.2023.12.003","article-title":"Androgen receptor-interacting proteins in prostate cancer development and therapy resistance","volume":"194","author":"Culig","year":"2024","journal-title":"Am. J. Pathol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"108363","DOI":"10.1016\/j.jbc.2025.108363","article-title":"Steroid receptors and coregulators: Dissemination of sex differences and emerging technologies","volume":"301","author":"Pauss","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/1878-0261.13030","article-title":"FKBP51 and FKBP52 regulate androgen receptor dimerization and proliferation in prostate cancer cells","volume":"16","author":"Maeda","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s41467-018-03573-6","article-title":"Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression","volume":"9","author":"Latonen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ccell.2019.02.005","article-title":"The proteogenomic landscape of curable prostate cancer","volume":"35","author":"Sinha","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Liyanage, C., Malik, A., Abeysinghe, P., Clements, J., and Batra, J. (2021). SWATH-MS based proteomic profiling of prostate cancer cells reveals adaptive molecular mechanisms in response to anti-androgen therapy. Cancers, 13.","DOI":"10.3390\/cancers13040715"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Sadeesh, N., Scaravilli, M., and Latonen, L. (2021). Proteomic landscape of prostate cancer: The view provided by quantitative proteomics, integrative analyses, and protein interactomes. Cancers, 13.","DOI":"10.3390\/cancers13194829"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Nevedomskaya, E., Sugawara, T., Baumgart, S.J., Lesche, R., Hahne, H., Mumberg, D., and Haendler, B. (2022). Comparative proteomic and transcriptomic analysis of the impact of androgen stimulation and darolutamide inhibition. Cancers, 15.","DOI":"10.3390\/cancers15010002"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"115828","DOI":"10.1016\/j.celrep.2025.115828","article-title":"An integrated proteomic portrait of prostate cancer progression","volume":"44","author":"Zhang","year":"2025","journal-title":"Cell Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccr.2012.11.010","article-title":"The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man","volume":"23","author":"Sharma","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1530\/ERC-19-0032","article-title":"Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers","volume":"26","author":"Stelloo","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Shen, M., Demers, L.K., Bailey, S.D., and Labbe, D.P. (2022). To bind or not to bind: Cistromic reprogramming in prostate cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.963007"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-020-14644-y","article-title":"Androgen receptor-binding sites are highly mutated in prostate cancer","volume":"11","author":"Morova","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"33510","DOI":"10.1038\/srep33510","article-title":"Global analysis of transcription in castration-resistant prostate cancer cells uncovers active enhancers and direct androgen receptor targets","volume":"6","author":"Toropainen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/1878-0261.12693","article-title":"Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation","volume":"14","author":"Baumgart","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1158\/1078-0432.CCR-21-3603","article-title":"Acetylated HOXB13 regulated super enhancer genes define therapeutic vulnerabilities of castration-resistant prostate cancer","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2017.330","article-title":"Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis","volume":"37","author":"Stelloo","year":"2018","journal-title":"Oncogene"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","article-title":"Prostate cancer reactivates developmental epigenomic programs during metastatic progression","volume":"52","author":"Pomerantz","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Gardner, E.J., Ponnusamy, S., and Adelaiye-Ogala, R. (2025). Coactivator networks orchestrating noncanonical AR programs in enzalutamide-resistant CRPC. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1748527"},{"key":"ref_138","first-page":"18","article-title":"Androgen receptor (AR) cistrome in prostate differentiation and cancer progression","volume":"5","author":"Wang","year":"2017","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/0008-5472.CAN-25-2747","article-title":"EZH2 suppression diversifies prostate cancer lineage variant evolution and lacks efficacy in inhibiting disease progression","volume":"86","author":"Jacobi","year":"2026","journal-title":"Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e34311","DOI":"10.7554\/eLife.34311","article-title":"Donated chemical probes for open science","volume":"7","author":"Muller","year":"2018","journal-title":"eLife"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e250529","DOI":"10.1530\/ERC-25-0529","article-title":"Molecular determinants of AR-enhancer interaction and cistrome reprogramming in prostate cancer progression","volume":"33","author":"Fernandes","year":"2026","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1038\/s41388-025-03573-z","article-title":"Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer","volume":"44","author":"Chukhu","year":"2025","journal-title":"Oncogene"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e28482","DOI":"10.7554\/eLife.28482","article-title":"A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer","volume":"6","author":"Liu","year":"2017","journal-title":"eLife"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1210\/me.2005-0348","article-title":"Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L\/F swapping","volume":"20","author":"Dubbink","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"12496","DOI":"10.3390\/ijms140612496","article-title":"Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer","volume":"14","author":"Lallous","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"R289","DOI":"10.1530\/JME-19-0034","article-title":"BAG1L: A promising therapeutic target for androgen receptor-dependent prostate cancer","volume":"62","author":"Lee","year":"2019","journal-title":"J. Mol. Endocrinol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e27159","DOI":"10.7554\/eLife.27159","article-title":"Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer","volume":"6","author":"Cato","year":"2017","journal-title":"eLife"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13046-020-01760-2","article-title":"ASC-J9(R) suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling","volume":"40","author":"Tian","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e14583","DOI":"10.1111\/cbdd.14583","article-title":"Synthesis of curcumin derivatives targeting androgen receptor for castration-resistant prostate cancer therapy","volume":"104","author":"Liu","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Baumgart, S.J., Nevedomskaya, E., and Haendler, B. (2019). Dysregulated transcriptional control in prostate cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20122883"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1158\/0008-5472.CAN-19-3447","article-title":"Shaping chromatin states in prostate cancer by pioneer transcription factors","volume":"80","author":"Hankey","year":"2020","journal-title":"Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e250070","DOI":"10.1530\/ERC-25-0070","article-title":"Identification of protein-coding genes associated with metastatic prostate cancer","volume":"32","author":"Sattari","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1038\/s41588-025-02388-8","article-title":"Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer","volume":"57","author":"Li","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"115312","DOI":"10.1016\/j.celrep.2025.115312","article-title":"CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer","volume":"44","author":"Xiang","year":"2025","journal-title":"Cell Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13238-020-00786-8","article-title":"Pioneer of prostate cancer: Past, present and the future of FOXA1","volume":"12","author":"Teng","year":"2021","journal-title":"Protein Cell"},{"key":"ref_156","first-page":"58","article-title":"Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance","volume":"6","author":"Gao","year":"2026","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/2159-8290.CD-21-0576","article-title":"Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence","volume":"12","author":"Linder","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41586-019-1347-4","article-title":"Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer","volume":"571","author":"Parolia","year":"2019","journal-title":"Nature"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1016\/j.molcel.2024.09.024","article-title":"Redirecting the pioneering function of FOXA1 with covalent small molecules","volume":"84","author":"Won","year":"2024","journal-title":"Mol. Cell."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00018-024-05209-z","article-title":"EP300\/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells","volume":"81","author":"Huttunen","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41467-025-67329-9","article-title":"BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction","volume":"17","author":"Jeon","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"116324","DOI":"10.1016\/j.celrep.2025.116324","article-title":"Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer","volume":"44","author":"Formaggio","year":"2025","journal-title":"Cell Rep."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.molcel.2009.10.020","article-title":"The homeodomain protein HOXB13 regulates the cellular response to androgens","volume":"36","author":"Norris","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/1541-7786.MCR-23-0086","article-title":"Hierarchical phosphorylation of HOXB13 by mTOR dictates its activity and oncogenic function in prostate cancer","volume":"21","author":"Chen","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e2500327122","DOI":"10.1073\/pnas.2500327122","article-title":"Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer","volume":"122","author":"Lingadahalli","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1073\/pnas.1718811115","article-title":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","volume":"115","author":"Chen","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrurol.2016.225","article-title":"The role of GATA2 in lethal prostate cancer aggressiveness","volume":"14","author":"Hoshida","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"18261","DOI":"10.1073\/pnas.1421415111","article-title":"GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex","volume":"111","author":"He","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/ERC-21-0085","article-title":"Inhibition of GATA2 in prostate cancer by a clinically available small molecule","volume":"29","author":"Kaochar","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"10104","DOI":"10.1093\/nar\/gkz790","article-title":"Molecular determinants for enzalutamide-induced transcription in prostate cancer","volume":"47","author":"Yuan","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccell.2019.03.001","article-title":"CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis","volume":"35","author":"Augello","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"20056","DOI":"10.1021\/acs.jmedchem.4c01172","article-title":"Discovery of CHD1 antagonists for PTEN-deficient prostate cancer","volume":"67","author":"Johnson","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s43018-025-00952-z","article-title":"CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors","volume":"6","author":"Chen","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"189560","DOI":"10.1016\/j.bbcan.2026.189560","article-title":"Molecular insights for the tumor suppressor role of SPOP in prostate cancer","volume":"1881","author":"Yan","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Watanabe, R., Miura, N., Kikugawa, T., and Saika, T. (2025). Precision medicine in prostate cancer with a focus on emerging therapeutic strategies. Biomedicines, 14.","DOI":"10.3390\/biomedicines14010052"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"109665","DOI":"10.1016\/j.celrep.2021.109665","article-title":"Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer","volume":"36","author":"Tewari","year":"2021","journal-title":"Cell Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41467-020-20820-x","article-title":"Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer","volume":"12","author":"Bernasocchi","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.molcel.2022.03.035","article-title":"Allosteric interactions prime androgen receptor dimerization and activation","volume":"82","author":"Wasmuth","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/1535-7163.MCT-23-0196","article-title":"A multivalent peptoid conjugate modulates androgen receptor transcriptional activity to inhibit therapy-resistant prostate cancer","volume":"22","author":"Habault","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_181","first-page":"73","article-title":"Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer","volume":"6","author":"Shuai","year":"2026","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Purohit, T.A., Bahr, K., Yang, B., Schultz, Z., Lewis, P.W., Denu, J.M., and Jarrard, D.F. (2025). Histone-modifying enzymes as drivers and therapeutic targets in androgen-resistant prostate cancer. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1730397"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/s44321-025-00282-8","article-title":"New frontiers in prostate cancer treatment from systemic therapy to targeted therapy","volume":"17","author":"Nouruzi","year":"2025","journal-title":"EMBO Mol. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41585-024-00991-8","article-title":"Prostate cancer epigenetics\u2014From pathophysiology to clinical application","volume":"22","author":"Constancio","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Wang, M.S., Sussman, J., Xu, J.A., Patel, R., Elghawy, O., and Rawla, P. (2024). Pharmacological advancements of PRC2 in cancer therapy: A narrative review. Life, 14.","DOI":"10.3390\/life14121645"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/ijc.32118","article-title":"Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer","volume":"145","author":"Liu","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1038\/s41467-021-26840-5","article-title":"Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression","volume":"12","author":"Bolis","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"118106","DOI":"10.1016\/j.ejmech.2025.118106","article-title":"Recent update on the development of EZH2 inhibitors and degraders for cancer therapy","volume":"299","author":"Tang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"TPS284","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS284","article-title":"MEVPRO-3: Phase III trial of mevrometostat plus enzalutamide (versus placebo plus enzalutamide) in metastatic castration-sensitive prostate cancer (mCSPC)","volume":"44","author":"Agarwal","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10142-025-01563-8","article-title":"Polycomb repressive complex 2 (PRC2) pathway\u2019s role in cancer cell plasticity and drug resistance","volume":"25","author":"Goleij","year":"2025","journal-title":"Funct. Integr. Genom."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/s41388-026-03828-3","article-title":"Histone methyltransferase KMT2D promotes castration-resistant prostate cancer progression by reactivating AR through FOXA1","volume":"45","author":"Luo","year":"2026","journal-title":"Oncogene"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1038\/s41467-018-07511-4","article-title":"NSD2 is a conserved driver of metastatic prostate cancer progression","volume":"9","author":"Aytes","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41588-024-01893-6","article-title":"NSD2 is a requisite subunit of the AR\/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis","volume":"56","author":"Parolia","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"TPS276","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS276","article-title":"Phase 1, dose-escalation study of KTX-2001 (an NSD2 inhibitor) alone and in combination with darolutamide for metastatic castration-resistant prostate cancer","volume":"44","author":"Abida","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/0008-5472.CAN-22-2433","article-title":"LSD1 inhibition disrupts super-enhancer-driven oncogenic transcriptional programs in castration-resistant prostate cancer","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1002\/ijc.31843","article-title":"Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer","volume":"143","author":"Lee","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Jeyapalan, J.N., Metzler, V.M., de Brot, S., Woodcock, C.L., Harris, A.E., Lothion-Roy, J., Nilsson, E.M., Ntekim, A., Toss, M.S., and Persson, J.L. (2026). KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer. Mol. Oncol.","DOI":"10.1002\/1878-0261.70238"},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Raith, F., O\u2019Donovan, D.H., Lemos, C., Politz, O., and Haendler, B. (2023). Addressing the reciprocal crosstalk between the AR and the PI3K\/AKT\/mTOR signaling pathways for prostate cancer treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032289"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1186\/s12967-025-07053-6","article-title":"CBP\/p300, a promising therapeutic target for prostate cancer","volume":"23","author":"Xu","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/s41388-024-03148-4","article-title":"AR coactivators, CBP\/p300, are critical mediators of DNA repair in prostate cancer","volume":"43","author":"Sardar","year":"2024","journal-title":"Oncogene"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"TPS5085","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5085","article-title":"The Courage study: A first-in-human phase 1 study of the CBP\/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer","volume":"39","author":"Armstrong","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"118489","DOI":"10.1016\/j.ejmech.2025.118489","article-title":"Discovery of CZL-077 as a potent, selective, and orally active p300\/CBP bromodomain inhibitor with improved in vivo antitumor efficacy","volume":"304","author":"Chen","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41588-025-02336-6","article-title":"Targeting histone H2B acetylated enhanceosomes via p300\/CBP degradation in prostate cancer","volume":"57","author":"Luo","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2025-3759","article-title":"EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)","volume":"146","author":"Fabris","year":"2025","journal-title":"Blood"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00345-018-2382-8","article-title":"The BET-inhibitor PFI-1 diminishes AR\/AR-V7 signaling in prostate cancer cells","volume":"37","author":"Hupe","year":"2019","journal-title":"World J. Urol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"10194","DOI":"10.1093\/nar\/gkad700","article-title":"HIRA-mediated loading of histone variant H3.3 controls androgen-induced transcription by regulation of AR\/BRD4 complex assembly at enhancers","volume":"51","author":"Morozov","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/epi.14.91","article-title":"Targeting BET bromodomains for cancer treatment","volume":"7","author":"Jung","year":"2015","journal-title":"Epigenomics"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13543784.2023.2186851","article-title":"Role of bromodomain and extraterminal (BET) proteins in prostate cancer","volume":"32","author":"Mandl","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A phase Ib\/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-22-0175","article-title":"Phase Ib study of the BET inhibitor GS-5829 as monotherapy and combined with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Aggarwal","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"104499","DOI":"10.1016\/j.esmoop.2025.104499","article-title":"Final results from the phase Ia\/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma","volume":"10","author":"Lauer","year":"2025","journal-title":"ESMO Open"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3892\/etm.2015.2796","article-title":"Anticancer activity of bicalutamide-loaded PLGA nanoparticles in prostate cancers","volume":"10","author":"Guo","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/03639045.2018.1562463","article-title":"Facile development, characterization, and evaluation of novel bicalutamide loaded pH-sensitive mesoporous silica nanoparticles for enhanced prostate cancer therapy","volume":"45","author":"Saroj","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Popova, T., Tzankov, B., Slavkova, M., Yordanov, Y., Stefanova, D., Tzankova, V., Tzankova, D., Spassova, I., Kovacheva, D., and Voycheva, C. (2025). Carboxylated mesoporous carbon nanoparticles as bicalutamide carriers with improved biopharmaceutical and chemo-photothermal characteristics. Molecules, 30.","DOI":"10.3390\/molecules30153055"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1021\/acs.molpharmaceut.7b01024","article-title":"Improvement in therapeutic efficacy and reduction in cellular toxicity: Introduction of a novel anti-PSMA-conjugated hybrid antiandrogen nanoparticle","volume":"15","author":"Thangavel","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/10717544.2022.2110998","article-title":"Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer","volume":"29","author":"Chen","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"16968","DOI":"10.1021\/acsomega.1c07254","article-title":"Systematic development of solid lipid nanoparticles of abiraterone acetate with improved oral bioavailability and anticancer activity for prostate carcinoma treatment","volume":"7","author":"Beg","year":"2022","journal-title":"ACS Omega"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"124869","DOI":"10.1016\/j.ijpharm.2024.124869","article-title":"Are Nanostructured Lipid Carriers (NLC) better than Solid Lipid Nanoparticles (SLN) for delivering abiraterone acetate through the gastrointestinal tract?","volume":"667","author":"Lemasson","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/10837450.2025.2505003","article-title":"Solid supersaturated self-nanoemulsifying drug delivery system for abiraterone acetate: Improved drug loading, dissolution, cellular uptake, and anticancer activity","volume":"30","author":"Nair","year":"2025","journal-title":"Pharm. Dev. Technol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"e6657773","DOI":"10.1002\/ange.6657773","article-title":"Nanozyme-mediated PROTACs delivery for targeted protein degradation and ferroptosis sensitization in prostate cancer","volume":"138","author":"Wang","year":"2026","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/pros.24309","article-title":"Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides","volume":"82","author":"Verhaegh","year":"2022","journal-title":"Prostate"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1007\/s13346-026-02051-7","article-title":"A mechanical reprogramming: Synergistic tumor microenvironment normalization improves nano-immunotherapy delivery in prostate cancer via multiphysics modeling","volume":"16","author":"Mirala","year":"2026","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"eaar3958","DOI":"10.1126\/science.aar3958","article-title":"Coactivator condensation at super-enhancers links phase separation and gene control","volume":"361","author":"Sabari","year":"2018","journal-title":"Science"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ccell.2020.12.003","article-title":"Biomolecular condensates and cancer","volume":"39","author":"Boija","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Takayama, K.I., and Inoue, S. (2022). Targeting phase separation on enhancers induced by transcription factor complex formations as a new strategy for treating drug-resistant cancers. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1024600"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41589-022-01151-y","article-title":"Targeting androgen receptor phase separation to overcome antiandrogen resistance","volume":"18","author":"Xie","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"e2211832120","DOI":"10.1073\/pnas.2211832120","article-title":"Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer","volume":"120","author":"Thiyagarajan","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1538-7445.AM2025-1751","article-title":"Beta-catenin c-mods are orally bioavailable small-molecules targeting Wnt-driven tumors","volume":"85","author":"Klein","year":"2025","journal-title":"Cancer Res."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CCO.0000000000000520","article-title":"Targeting the androgen receptor and overcoming resistance in prostate cancer","volume":"31","author":"Einstein","year":"2019","journal-title":"Curr. Opin. Oncol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euf.2024.07.012","article-title":"Targeting androgen receptor alterations in metastatic prostate cancer","volume":"11","author":"Rajwa","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41585-025-01042-6","article-title":"Synergistic targeting strategies for prostate cancer","volume":"22","author":"Li","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Chen, Y., and Lan, T. (2024). N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: A comprehensive review. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1451957"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"bqag056","DOI":"10.1210\/endocr\/bqag056","article-title":"Breaking the bonds: Targeting protein dimerization for prostate cancer therapy","volume":"167","author":"Singh","year":"2026","journal-title":"Endocrinology"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.eururo.2025.06.013","article-title":"Novel therapeutic strategies for metastatic prostate cancer care","volume":"88","author":"Cimadamore","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Lumahan, L.E.V., Arif, M., Whitener, A.E., and Yi, P. (2024). Regulating androgen receptor function in prostate cancer: Exploring the diversity of post-translational modifications. Cells, 13.","DOI":"10.3390\/cells13020191"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cbf.3401","article-title":"Targeting the signalling pathways regulated by deubiquitinases for prostate cancer therapeutics","volume":"37","author":"Islam","year":"2019","journal-title":"Cell Biochem. Funct."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.1093\/nar\/gkae653","article-title":"Central role of SUMOylation in the regulation of chromatin interactions and transcriptional outputs of the androgen receptor in prostate cancer cells","volume":"52","author":"Launonen","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12032-025-02859-2","article-title":"Emerging roles and clinical perspectives of long noncoding RNAs in prostate cancer","volume":"42","author":"Kumar","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Dziubanska-Kusibab, P.J., Nevedomskaya, E., and Haendler, B. (2024). Preclinical anticipation of on- and off-target resistance mechanisms to anti-cancer drugs: A systematic review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25020705"},{"key":"ref_241","first-page":"88","article-title":"Genetic and epigenetic mechanisms underlying treatment-induced neuroendocrine prostate cancer","volume":"6","author":"Keo","year":"2026","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Fatima, S.A., Haider, K.H., Qutubuddin, S., Begum, Y., Stevenson, M., Fatima, K., Anwar, E.I., and Barg, M. (2026). The emerging trends in prostate cancer treatment: A systematic review of the literature. J. Chemother., 1\u201316.","DOI":"10.1080\/1120009X.2026.2718574"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2026.44.7_suppl.17","article-title":"Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC)","volume":"44","author":"Boni","year":"2026","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8200\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:33:35Z","timestamp":1789464815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":243,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188200"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188200","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}